Contact Us

Oxford Vacmedix

Home
Author: Oxford Vacmedix
Page 3
Company News September 8, 2022 Oxford Vacmedix Comments: 0

OVM-200 Phase 1 Clinical Trial featured on TV

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder of OVM said: We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack the...
Read More
Company News July 27, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test

New patent for a novel diagnostic test to detect anti-microbial resistance filed, after successful completion of development and initial testing Oxford, 27th July 2022 Press Release – Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test Oxford Vacmedix (OVM), the UK clinical stage biopharma company, focused on the development of a new generation of cancer vaccines, announced today that project work to develop a novel diagnostic test for anti-microbia...
Read More
Publications
June 22, 2022 Oxford Vacmedix Comments: 0

In Vitro and In Vivo Antigen Presentation and Diagnosis Development of Recombinant Overlapping Peptides Corresponding to Mtb ESAT-6/CFP-10

The following publication describes a study developing the ROP-TB antigen for both in vitro IGRA-based TB diagnosis, as well as the in vivo skin test for TB diagnosis in both humans and cattle.  The advantages of the ROP-TB diagnosis are firstly distinguishing Mtb infection from BCG vaccination, and secondly, being suitable for industrial manufacture. Read the full article: ROP-TB Diagnosis By Qing Zhang, Xiong Lu, Liang Gao, Siyu Tao, Yinghua Ge, Daocheng Cui, Renying Zhu, Wenshu Lu, Jian Wang...
Read More
Company News May 25, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays.  Project with Department of Oncology, University of Oxford and Reading Scientific Services (RSSL) to develop the methodology for T-cell potency assays of vaccines. Oxford, 25th May 2022 Press Release – Innovate UK funding for development of novel T-cell potency assays Oxford Vacmedix UK Limited (OVM) announced today the award of a Small Business Research Initiative contract from Innovate UK to fu...
Read More
Company News May 23, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix founder Dr Shisong Jiang invited to Buckingham Place

Dr Shisong Jiang recieved an invitation to the annual Royal Garden Party to recognise many years’ service to charity. Oxford, 23rd May 2022 Press Release – Dr Shisong Jiang invited to Buckingham Palace On Wednesday 18 May, the Dr Shisong Jiang, the founder and CSO of Oxford Vacmedix, was invited to Buckingham Palace in London for the Royal Garden Party, an annual event that invites a broad range of people – all of whom have made a positive impact in their community – to be re...
Read More
Publications
May 11, 2022 Oxford Vacmedix Comments: 0

Editorial: Research, Development and Clinical Trials for Peptide-Based Vaccines

From the eradication of smallpox through to the global response to the COVID-19 pandemic, vaccines have been a cornerstone in the fight against infectious diseases in humans and livestock since the 18th century. Although vaccines against COVID-19 are unlikely to eradicate the disease in the way that the smallpox vaccine did, they have proved very effective in preventing death and hospitalisation, with enormous societal and economic benefits. There is now considerable research effort invested in...
Read More
Publications
May 11, 2022 Oxford Vacmedix Comments: 0

HPV-16 E7-Specific Cellular Immune Response

HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study High-risk human papillomavirus (HPV) infection is the cause of almost all cervical cancers. HPV16 is one of the main risk subtypes. Although screening programs have greatly reduced the prevalence of cervical cancer in developed countries, current diagnostic tests cannot predict if mild lesions may progress into invasive lesion...
Read More
Publications
May 11, 2022 Oxford Vacmedix Comments: 0

Survivin as a biological biomarker for diagnosis and therapy

Survivin (SVN) is a member of the inhibitor of apoptosis (IAP) protein family that promotes cellular proliferation and inhibits apoptosis. Overexpression of SVN is associated with autoimmune disease, hyperplasia, and tumors and can be used as a biomarker in these diseases. SVN is widely recognized as a tumor-associated antigen (TAA) and has become an important target for cancer diagnosis and treatment. Read the full article: Survivn as a biological biomarker for diagnosis and therapy By: Yuming...
Read More
Company News November 4, 2021 Oxford Vacmedix Comments: 0

First patient treated with novel Cancer Vaccine

A Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has started – the first clinical trial of a cancer vaccine using the novel technology. Press Release – Oxford group announces first patient treated with novel cancer vaccine Oxford, 4th November 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the start of a Phase 1 trial of OVM-200 with the first patient being treated at the prestigious Sarah...
Read More
Company News August 10, 2021 Oxford Vacmedix Comments: 0

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 trial of OVM-200 has been received from the MHRA (Medicines and Healthcare products Regulatory Authority). Ethics approval for the trial has al...
Read More
en_GBEnglish
en_GBEnglish